Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus Chemotherapy in Advanced Biliary Tract Carcinoma (China Extension)
NCT04924062Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2020
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in biliary tract carcinoma (BTC), sponsored by Merck & Co.. Started Jul 2020; status: completed.
02
Drugs
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT04924062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04924062.